The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies.
Sign Up to like & getrecommendations! Published in 2020 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2020.115018
Abstract: The incorporation of mesenchymal-epithelial transition factor (c-Met) inhibitors with conventional chemotherapeutics may increase the anticancer efficacy of chemotherapeutic agents, but bears the risk of enhancing the adverse effects. To test the hypothesis, co-administration of the… read more here.
Keywords: capmatinib; cardiotoxicity; inhibitor capmatinib; dox ... See more keywords
Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835920913426
Abstract: [This corrects the article DOI: 10.1177/1758835919889001.]. read more here.
Keywords: efficacy safety; safety met; study efficacy; erratum phase ... See more keywords
Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20541
Abstract: e20541Background: Approximately 3-4% of lung adenocarcinomas express a truncated form of c-Met (c-Metex14) due to mutation-induced exon 14 skipping. c-Metex14 accumulates on the cell surface and is constitutively active with the ability to drive NSCLC.… read more here.
Keywords: lung adenocarcinoma; inhibitor tepotinib; tepotinib; exon skipping ... See more keywords